Cost structure and clinical outcome of a stem cell transplantation programin a developing country: The experience in Northeast Mexico

Oncologist

Volumn 20, Issue 4, 2015, Pages 386-392

  Jaime Pérez, José Carlos ^a   Heredia Salazar, Alberto Carlos ^a   Cantú Rodríguez, Olga G ^a   Gutiérrez Aguirre, Homero ^a   Villarreal Villarreal, César Daniel ^a   Mancías Guerra, Consuelo ^a   Herrera Garza, José Luís ^a   Gómez Almaguer, David ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Hematopoietic stem cell transplant; HSCT cost containment; HSCT cost structure; HSCT costs; HSCT in developing countries; Out of pocket expenses

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGRAFT; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; FEMALE; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THALASSEMIA; ALLOTRANSPLANTATION; COST; DEVELOPING COUNTRY; ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MEXICO; TREATMENT OUTCOME;

COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MEXICO; THALASSEMIA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84927588605     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0218     Document Type: Article

References (40)

1. Duncan N, Hewetson M, Powles R et al. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1996; 18: 1175-1178.
2. Barr RD. The importance of lowering the costs of stem cell transplantation in developing countries. Int J Hematol 2002; 76(suppl 1): 365-367.
3. Gómez-Almaguer D. The simplification of the SCTprocedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 2002; 76(suppl 1): 380-382.
4. Barr RD. Costs and consequences of stem cell transplantation in children. PediatrTransplant 2003; 7(suppl 3): 7-11.
5. Weeks FM, Yee GC, Bartfield AA et al. The true cost of bone marrow transplantation. Am JMed Sci 1997; 314: 101-112.
6. Barr R, Furlong W, Henwood J et al. Economic evaluation of allogeneic bone marrow transplantation: Arudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996; 14: 1413-1420.
7. Durbin M. Bone marrow transplantation: Economic, ethical, and social issues. Pediatrics 1988; 82: 774-783.
8. Baron F, Copizza S, Baudoux E et al. CD341cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer. Haematologica 2004; 89: 1146-1148.
9. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: Report of four cases. Bone Marrow Transplant 2000; 25: 131-133.
10. Ruiz-Delgado GJ, Gutierrez-Riveroll KI, Gutierrez-Aguirre CH et al. A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting. Blood Transfus 2009; 7: 127-131.
11. Ruiz-Argüelles GJ, Gómez-Almaguer D. The Mexican approach to conduct nonmyeloablative stem cell transplantation should not be overlooked. Int J Hematol 2003; 77: 526-527.
12. Ruiz-Argüelles GJ, Gómez-Almaguer D, L ópez-Martínez B et al. Results of an allogeneic nonmyeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894-896.
13. Ruiz-Argüelles GJ. Non-myeloablative bonemarrow transplantation. ArchMed Res 2003; 34: 554-557.
14. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Delgado GJ et al. [Eight years using the "Mexican method" for allogeneic hematopoietic stem cell transplants]. Gac Med Mex 2007; 143: 231-235.
15. Herrera-Garza J, Jaime-Pérez J, Montemayor J et al. High-dose peripheral blood stem cell transplant formultitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen. Bone Marrow Transplant 1999; 24: 845-848.
16. Gooley TA, Chien JW, PergamSA et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
17. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002; 76(suppl 1): 376-379.
18. Gomez-Almaguer D, Ruiz-Arguelles GJ, Tarin-Arzaga Ldel C et al. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transplant 2003; 9: 157-161.
19. Ruiz-Argüelles GJ, Gómez-Almaguer D. Breaking dogmata to help patients: Non-myeloablative haematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693-1699.
20. Majhail NS, Mothukuri JM, Brunstein CG et al. Costs of hematopoietic cell transplantation: Comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009; 15: 564-573.
21. Saito AM, Zahrieh D, Cutler C et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant 2007; 40: 209-217.
22. Cordonnier C, Maury S, Esperou H et al. Do minitransplants have minicosts?: A cost comparison between myeloablative and nonmyeloablative allogeneic stemcell transplant in patients with acutemyeloid leukemia. BoneMarrow Transplant 2005; 36: 649-654.
23. Ngamkiatphaisan S, Sriratanaban J, Kamolratanakul P et al. Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital. JMed Assoc Thai 2007; 90: 2565-2573.
24. Blommestein HM, Verelst SG, Huijgens PC et al. Real-world costs of autologous and allogeneic stemcell transplantations for haematological diseases: A multicentre study. Ann Hematol 2012; 91: 1945-1952.
25. Bennett C, Waters T, Stinson T et al. Valuing clinical strategiesearlyindevelopment: Acostanalysis of allogeneic peripheral blood stem cell transplantation. BoneMarrow Transplant 1999; 24: 555-560.
26. Couban S, Dranitsaris G, Andreou P et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: A Canadian perspective. Bone Marrow Transplant 1998; 22: 1199-1205.
27. Sánchez-Blanco JJ, Lozano ML, deArriba F et al. [Economic cost of peripheral blood progenitor cell transplantation in Spain]. Med Clin (Barc) 2004; 123: 401-405.
28. Vicent MG, Madero L, Chamorro L et al. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica 2001; 86: 1087-1094.
29. Madero L, González Vincent M, Ramirez M et al. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. BoneMarrowTransplant 2000; 26: 269-273.
30. Abdel-Rahman F, Hussein A, Rihani R et al. Bone marrow and stem cell transplantation at King Hussein cancer center. Bone Marrow Transplant 2008; 42(suppl 1): S89-S91.
31. Majhail NS, Mau LW, Denzen EM et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: A study using a large national private claims database. Bone Marrow Transplant 2013; 48: 294-300.
32. Cantú-Rodríguez OG, Jaime-Pérez JC, Gutiérrez-Aguirre CH et al. Outpatient allografting using nonmyeloablative conditioning: The Mexican experience. BoneMarrow Transplant 2007; 40: 119-123.
33. Meehan KR, Fitzmaurice T, Root L et al. The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients. J Support Oncol 2006; 4: 187-190.
34. Frey P, Stinson T, Siston A et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant 2002; 30: 741-748.
35. Saito AM, Cutler C, Zahrieh D et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008; 14: 197-207.
36. Redaelli A, Botteman MF, Stephens JM et al. Economic burden of acute myeloid leukemia: A literature review. Cancer Treat Rev 2004; 30: 237-247.
37. Majhail NS, Mothukuri JM, Macmillan ML et al. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer 2010; 54: 138-143.
38. Khera N, Emmert A, Storer BE et al. Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens. The Oncologist 2014; 19: 639-644.
39. Cant ú-Rodríguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC et al. Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. Eur J Haematol 2011; 87: 521-530.
40. Ruiz-Argüelles GJ, Gómez-Almaguer D, David-Gomez-Rangel J et al. Allogeneic hematopoietic stem cell transplantationwith non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: A prospective study. Leuk Lymphoma 2004; 45: 1191-1195.